ClinicalTrials HQ

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies

Recruiting · NCT07284433 · Registry updated 2026-08-28
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell MalignanciesB-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasmRecruitingPhase 1 / Phase 22026-08-28NCT07284433

2 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
AvenCell Europe GmbH3
AvenCell Therapeutics, Inc.2

13 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Brown University HealthProvidenceUnited States5
Charité Universitätsmedizin BerlinBerlinGermany15
Klinikum der Universität MünchenMunichGermany2
MD Anderson Cancer CenterHoustonUnited States589
Northwestern UniversityEvanstonUnited States53
Sarah Cannon Research InstituteNashvilleUnited States119
Uniklinikum ErlangenEssenGermany1
University of ChicagoChicagoUnited States312
Universitätsklinikum DresdenDresdenGermany5
Universitätsklinikum ErlangenErlangenGermany18
Universitätsklinikum Hamburg-EppendorfHamburgGermany29
Universitätsklinikum MarburgMarburgGermany2
Universitätsklinikum UlmUlmGermany17